Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“New data in Blood challenges the chronobiology narrative in CAR-T
In a large multi-center Australian cohort (n=584), time of CAR-T infusion (morning vs afternoon) did NOT significantly impact PFS or OS after adjusting for key clinical variables.
Despite prior reports suggesting earlier infusions may improve outcomes, this analysis found no clinically meaningful difference – even after sensitivity analyses and spline modeling
Bottom line:
For patients with LBCL receiving axi-cel or tisa-cel, established disease and patient factors matter far more than the hour on the clock.
An important reminder that in real-world cellular therapy, biology > scheduling.
“Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma” (Blood).”
Title: Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma
Authors: Mark R DowlingCorresponding Author, Edward Robert Scheffer Cliff, Anthony Jeffrey, Catelyn Cashion, Stephen Boyle, Jian Li, Thomas Buss, Ross MacDonald, Anastasia Edelkina, Hamish W Scott, MD, Nicole O’Leary, Michelle Wendy Keir, Safia Belbachir, David A Westerman, Constantine S. Tam, P. Joy Ho, Simon J Harrison, Allison Barraclough, Shafqat Inam, Emily Blyth, Andrea S. Henden, Vinay Vanguru, Michael Dickinson
Read the full article.
Other articles featuring Yan Leyfman on OncoDaily.